Drug Profile
Research programme: vaccines - Capo Therapeutics
Alternative Names: Anti-Aβ vaccine - Capo Therapeutics; Anti-tau vaccine - Capo Therapeutics; Anti-β amyloid vaccine - Capo Therapeutics; AV-1980R/ALatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Flinders University; Institute for Molecular Medicine; University of California at Irvine
- Developer Capo Therapeutics
- Class Alzheimer vaccines; DNA vaccines; Protein vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease(Prevention) in USA (Parenteral)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Parkinson's-disease(Prevention) in USA (Parenteral)
- 01 Mar 2021 Preclinical development is still ongoing for Alzheimer's disease (Prevention) and Parkinson's disease (Prevention) in USA (Parenteral) (Capo Therapeutics pipeline, March 2021)